Oral Ivermectin for Chikungunya Viral Infection
- Registration Number
- NCT06259383
- Lead Sponsor
- Prince of Songkla University
- Brief Summary
Chikungunya viral infection (CVI) is a mosquito-borne infection, caused by chikungunya virus (CHIKV), an alphavirus, belonging to the family Togaviridae. This infection causes febrile illness associated with high fever, rash, acute deliberating and persistent arthralgia. There is no licensed vaccine or specific treatment for this infection. Ivermectin (IVM), commonly-used antiparasitic, has been demonstrated to inhibit replication of CHIKV.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
- patients with virologic confirmation of chikungunya infection who had symptoms less than 72 hours prior to visit
- patients with virologic confirmation of chikungunya infection who had symptoms more than 72 hours prior to visit
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Patients received oral ivermectin, adjunctive to conventional treatment Ivermectin -
- Primary Outcome Measures
Name Time Method Day of fever clearance 1 week 120 participants would be under Body Temperature Assessment - the staff would assess once daily until the fever clearance was below 38C and the measure proportion of patients with fever clearance in each day of assessment until fever clearance at least in 7 days
- Secondary Outcome Measures
Name Time Method Day of virologic clearance 1 week 120 participants would be obtained blood examination for virological testing every day until virological clearance at least in 7 days
Trial Locations
- Locations (1)
Prince of Songkla University
🇹🇭Hat Yai, Songkhla, Thailand